S100A8/A9 in Kidney Diseases: Mechanisms, Spatiotemporal Regulation, Biomarker Potential, and Therapeutic Implications
Journal of Inflammation Research · 2026-09 · Volume 19 · 1-18
DOI: 10.2147/jir.s634929 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inflammation Research, 2026-09. Verfasst von Meng-Ge Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
S100A8/A9 (calprotectin) is increasingly recognized as an inflammatory mediator and a potential biomarker and therapeutic target in kidney diseases. However, its roles appear to vary across different stages and contexts of renal injury and repair, yet these changes remain incompletely understood. This narrative review synthesizes evidence from PubMed, Web of Science, and Scopus, supplemented by manual reference screening. Current evidence indicates that S100A8/A9 promotes immune activation, tubular injury, and fibrotic remodeling in diverse renal disorders. Emerging findings further suggest that its effects vary according to disease stage, cellular source, receptor usage, and the local microenvironment, with S100A8/A9 predominantly amplifying early inflammatory injury while potentially contributing to inflammation resolution and tissue repair at later stages. We therefore propose a spatiotemporal framework that extends beyond previous disease- or pathway-centered perspectives by integrating the timing and cellular context of S100A8/A9 signaling. Altered S100A8/A9 levels in blood, urine, feces, and extracellular vesicles also show potential for disease detection, differential diagnosis, monitoring, and prognostic assessment, while pharmacological inhibition of this axis has produced renoprotective effects in preclinical models. Nevertheless, heterogeneous models, limited cell- and receptor-specific evidence, uncertain therapeutic windows, and insufficient prospective clinical validation hinder translation. Longitudinal clinical studies and spatial and single-cell analyses are needed to establish stage-specific biomarker and therapeutic strategies targeting S100A8/A9 in precision nephrology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- Key Laboratory of Precise Prevention and Treatment of Rheumatism Syndrome of Renal Wind Disease, Hangzhou, Zhejiang, People's Republic of China.
ORCID-Profile: Meng-Ge Zhu, Meng-Dan Lu, Jia-Wei Cao, Yue-Wen Tang, Feng Wan
Zitieren
APA
Zhu, M. G., Lu, M. D., Cao, J. W., Tang, Y. W., & Wan, F. (2026). S100A8/A9 in Kidney Diseases: Mechanisms, Spatiotemporal Regulation, Biomarker Potential, and Therapeutic Implications. Journal of Inflammation Research, Volume 19, 1-18. https://doi.org/10.2147/jir.s634929
Vancouver
Zhu MG, Lu MD, Cao JW, Tang YW, Wan F. S100A8/A9 in Kidney Diseases: Mechanisms, Spatiotemporal Regulation, Biomarker Potential, and Therapeutic Implications. Journal of Inflammation Research. 2026;Volume 19:1-18. doi:10.2147/jir.s634929
BibTeX
@article{Zhu2026,
author = {Zhu, Meng-Ge and Lu, Meng-Dan and Cao, Jia-Wei and Tang, Yue-Wen and Wan, Feng},
title = {S100A8/A9 in Kidney Diseases: Mechanisms, Spatiotemporal Regulation, Biomarker Potential, and Therapeutic Implications},
journal = {Journal of Inflammation Research},
year = {2026},
volume = {Volume 19},
pages = {1--18},
doi = {10.2147/jir.s634929}
}
EUVIMED